​

Tarsus Pharmaceuticals (TARS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Tarsus Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$182.95M

Latest Revenue (Q)

$48.12M

Main Segment (Y)

Product

Tarsus Pharmaceuticals Revenue by Period

Tarsus Pharmaceuticals Revenue by Year

DateRevenueChange
2024-12-31$182.95M948.62%
2023-12-31$17.45M-32.42%
2022-12-31$25.82M-54.73%
2021-12-31$57.03M100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31--

Tarsus Pharmaceuticals generated $182.95M in revenue during NA 2024, up 948.62% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Tarsus Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-09-30$48.12M17.90%
2024-06-30$40.81M47.80%
2024-03-31$27.61M111.18%
2023-12-31$13.08M598.88%
2023-09-30$1.87M-87.75%
2023-06-30$15.28M511.08%
2023-03-31$2.50M-75.00%
2022-12-31$10.00M100.00%
2022-09-30--100.00%
2022-06-30$15.28M2734.32%
2022-03-31$539.00K59.47%
2021-12-31$338.00K-72.74%
2021-09-30$1.24M-94.37%
2021-06-30$22.02M-34.14%
2021-03-31$33.43M100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2018-06-30-100.00%
2018-03-31--

Tarsus Pharmaceuticals generated $48.12M in revenue during Q3 2024, up 17.90% compared to the previous quarter, and up 314.97% compared to the same period a year ago.

Tarsus Pharmaceuticals Revenue Breakdown

Tarsus Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21
Product$180.06M$14.73M--
License Fees and Collaboration$2.89M$2.72M$955.00K$2.08M
Collaboration Revenue--$1.92M$3.96M
License and Service--$23.89M$53.07M

Tarsus Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (98.42%), and License Fees and Collaboration (1.58%).

Quarterly Revenue by Product

Product/ServiceDec 24Sep 24Mar 24Dec 23Sep 23Mar 23Dec 22Jun 22Mar 22Sep 21Jun 21Mar 21
Product$107.22M$48.12M$24.72M$13.08M$1.65M-------
License And Collaboration--$2.89M$218.00K$2.50M$522.00K$33.00K$65.00K$737.00K$1.30M--
License and Service------$10.00M$13.89M-$708.00K$19.05M$33.31M
Collaboration-------$1.38M$539.00K$532.00K$2.97M$121.00K

Tarsus Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product (100.00%).

Tarsus Pharmaceuticals Revenue Breakdown by Country

Quarterly Revenue by Country

CountryMar 23Dec 22Jun 22Mar 22Sep 21Jun 21Mar 21
License And Collaboration$2.50M$522.00K$33.00K$65.00K$737.00K$1.30M-
License and Service-$10.00M$13.89M-$708.00K$19.05M$33.31M
Collaboration--$1.38M$539.00K$532.00K$2.97M$121.00K

Tarsus Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 23: License And Collaboration (100.00%).

Tarsus Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
TVTXTravere Therapeutics$233.18M$62.90M
TRDAEntrada Therapeutics$210.78M$19.57M
TARSTarsus Pharmaceuticals$182.95M$48.12M
GLUEMonte Rosa Therapeutics$75.62M$4.70M
ETONEton Pharmaceuticals$39.01M$10.32M
STOKStoke Therapeutics$36.55M$4.89M
GNFTGenfit$28.57M$17.08M
CNTBConnect Biopharma$26.03M-
NUVBNuvation Bio$7.87M$727.00K
HOWLWerewolf Therapeutics$1.89M$1.14M
RLYBRallybio$636.00K$299.00K
OPTOpthea$108.41K$61.27K
IKNAIkena Oncology--
DSGNDesign Therapeutics--
ALDXAldeyra Therapeutics--
PHVSPharvaris--
NUVLNuvalent--
ABOSAcumen Pharmaceuticals--
CNTACentessa Pharmaceuticals--
PEPGPepGen--
TYRATyra Biosciences--
ELDNEledon Pharmaceuticals--

TARS Revenue FAQ

What is Tarsus Pharmaceuticals’s yearly revenue?

Tarsus Pharmaceuticals's yearly revenue for 2024 was $182.95M, representing an increase of 948.62% compared to 2023. The company's yearly revenue for 2023 was $17.45M, representing a decrease of -32.42% compared to 2022. TARS's yearly revenue for 2022 was $25.82M, representing a decrease of -54.73% compared to 2021.

What is Tarsus Pharmaceuticals’s quarterly revenue?

Tarsus Pharmaceuticals's quarterly revenue for Q3 2024 was $48.12M, a 17.90% increase from the previous quarter (Q2 2024), and a 2471.78% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $40.81M, a 47.80% increase from the previous quarter (Q1 2024), and a 167.15% increase year-over-year (Q2 2023). TARS's quarterly revenue for Q1 2024 was $27.61M, a 111.18% increase from the previous quarter (Q4 2023), and a 1004.56% increase year-over-year (Q1 2023).

What is Tarsus Pharmaceuticals’s revenue growth rate?

Tarsus Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 608.68%, and for the last 5 years (2020-2024) was 0%.

What are Tarsus Pharmaceuticals’s revenue streams?

Tarsus Pharmaceuticals's revenue streams in c 24 are Product, and License Fees and Collaboration. Product generated $180.06M in revenue, accounting 98.42% of the company's total revenue, up 1122.48% year-over-year. License Fees and Collaboration generated $2.89M in revenue, accounting 1.58% of the company's total revenue, up 6.48% year-over-year.

What is Tarsus Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Tarsus Pharmaceuticals was Product. This segment made a revenue of $180.06M, representing 98.42% of the company's total revenue.